ClinicalTrials.gg
Not yet recruitingNCT07332429Updated Nov 18, 2026

Efficacy and Safety of Alcovit in Reducing Blood Alcohol Concentration

An interventional study of Alcovit® (Zeolite Clinoptilolite) and Placebo in Alcohol Drinking, Blood Alcohol Content and Hangover, sponsored by Galzu Institute of Research, Teaching, Science and Applied Technology. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Galzu Institute of Research, Teaching, Science and Applied Technology · Not applicable, Interventional, and Prevention

How we know

Updated Nov 18, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if Alcovit® (zeolite clinoptilolite) works to reduce blood alcohol concentration in healthy adults aged 18-70 years who are occasional or moderate alcohol consumers. It will also learn about the safety and tolerability of Alcovit®. The main questions it aims to answer are:

  • Does Alcovit® reduce blood alcohol concentration when administered before or after standardized alcoholic beverage consumption compared to placebo?
  • What is the rate of alcohol elimination from the blood (mg/dL/hour) in participants taking Alcovit® compared to placebo?
  • Is Alcovit® well tolerated when administered before or after alcohol consumption?

Researchers will compare Alcovit® administered before alcohol consumption, Alcovit® administered after alcohol consumption, placebo administered before alcohol consumption, and placebo administered after alcohol consumption to see if Alcovit® effectively reduces blood alcohol levels.

Participants will:

  • Consume a standardized alcoholic beverage under controlled conditions;
  • Take Alcovit® or a placebo either 2-3 minutes before or after (within 5 minutes) alcohol consumption;
  • Have blood samples collected at baseline (30 minutes before), and at 20, 40, and 60 minutes after alcohol consumption to measure blood alcohol concentration;
  • Complete breathalyzer (etilometer) measurements at the same time points;
  • Answer questionnaire to assess alcohol hangover severity;
  • Have safety blood tests performed to monitor liver and kidney function.
Read the detailed description

The product has extensive international experience, having been marketed in several countries (Germany, Poland, Romania, Russia, Australia, Mexico, Colombia, Croatia, United States, Ukraine and Sweden) over the past 15 years, totaling 1,387,500 sachets sold without reports of toxicity.

The safety of clinoptilolite zeolite has been extensively evaluated by the European Food Safety Authority (EFSA) and by clinical trials, which confirmed its safety at typical food exposure levels, with no toxic side effects observed in humans or animals, even with prolonged use.

Alcovit® is formulated as an effervescent powder for suspension presented in 15g sachets and intended for healthy adults who are occasional or moderate consumers of alcoholic beverages.

The mechanism of action of Alcovit® is based on the ability of clinoptilolite zeolite to adsorb alcohol molecules in the stomach and small intestine, preventing their systemic absorption and promoting their natural elimination through the gastrointestinal tract.

02

Conditions studied

  • Alcohol Drinking
  • Blood Alcohol Content
  • Hangover

Browse trials for

Keywords

  • Zeolite Clinoptilolite
  • Alcovit
  • Alcohol Absorption
  • Medical Device
  • Hangover Prevention
  • Blood Alcohol Concentration
03

In context

Alcohol Drinking

703 studies on the registry are indexed under Alcohol Drinking; 132 are open to participants now.

This study's planned enrollment of 228 is above the median of 125 across 609 interventional studies indexed under Alcohol Drinking.

Browse Alcohol Drinking studies →

Lead sponsor

Galzu Institute of Research, Teaching, Science and Applied Technology is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 18 to 70 years;
  • Occasional or moderate alcohol consumers;
  • Willing to abstain from alcohol and Alcovit® for a period established in the study;
  • Voluntary willingness to participate in the study and sign the Form (ICF);
  • Availability to comply with the study schedule.

Exclusion criteria

Exclusion Criteria:

  • History of alcohol use disorder (alcoholism) or abuse of other illicit substances;
  • Hepatic, renal, gastrointestinal diseases, diabetes, and chronic conditions;
  • Use of medications that interact with alcohol, including but not limited to: non-steroidal anti-inflammatory drugs (NSAIDs such as ibuprofen, diclofenac, naproxen), analgesics, antibiotics, antidepressants, benzodiazepines, anticoagulants, or any other medication that may interfere with alcohol metabolism or increase risks associated with alcohol consumption;
  • Pregnancy or breastfeeding (beta-hCG test will be performed);
  • Known allergy to any component of Alcovit® or placebo;
  • Patients already enrolled in other clinical trials;
  • Inability to provide free and ;
  • Any medical condition or medical history that, in the investigator's opinion, may discourage participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
228 participants (estimated)

Study arms

  • Experimental
    Alcovit (Pre-consumption)

    Participants receive the investigational device immediately before (2-3 minutes) consuming the standardized alcohol dose.

    Device: Alcovit® (Zeolite Clinoptilolite)

  • Experimental
    Alcovit (Post-consumption)

    Participants receive the investigational device immediately after (maximum 5 minutes) consuming the standardized alcohol dose.

    Device: Alcovit® (Zeolite Clinoptilolite)

  • Placebo comparator
    Placebo (Pre-consumption)

    Participants receive the placebo immediately before consuming the standardized alcohol dose.

    Device: Placebo

  • Placebo comparator
    Placebo (Post-consumption)

    Participants receive the placebo immediately after consuming the standardized alcohol dose.

    Device: Placebo

Interventions

  • DeviceAlcovit® (Zeolite Clinoptilolite)

    Effervescent powder for oral suspension presented in 15g sachets, containing zeolite clinoptilolite (approximately 96% of the formulation) associated with B-complex vitamins (B1, B6, B12), vitamin C, and cupric chlorophyllin as natural colorant. The device is administered either immediately before alcohol consumption (2-3 minutes prior) or immediately after alcohol consumption (maximum 5 minutes after) depending on the assigned study arm.

    Also known as: Alcovit (Pre-consumption), Alcovit (Post-consumption)

  • DevicePlacebo

    Effervescent powder for oral suspension presented in 15g sachets. Inert substance with identical appearance, taste, and texture to Alcovit®, but without the active ingredient (zeolite clinoptilolite). The placebo is administered either immediately before alcohol consumption (2-3 minutes prior) or immediately after alcohol consumption (maximum 5 minutes after) depending on the assigned study arm.

    Also known as: Placebo (Pre-consumption), Placebo (Post-consumption)

06

What researchers measure

Primary outcomes

  1. Reduction in Blood Alcohol Levels and Breathalyzer Readings - Pre-consumption Administration

    Analysis of the reduction in blood alcohol levels and breathalyzer (ethylometer) readings in the Alcovit® group compared to the placebo group before alcohol consumption.

    Time frame: Baseline (30 minutes before), 20 minutes, 40 minutes, and 60 minutes after alcohol consumption (Day 1)

  2. Reduction in Blood Alcohol Levels and Breathalyzer Readings - Post-consumption Administration

    Analysis of the reduction in blood alcohol levels and breathalyzer (ethylometer) readings in the Alcovit® group compared to the placebo group after alcohol consumption.

    Time frame: Baseline (30 minutes before), 20 minutes, 40 minutes, and 60 minutes after alcohol consumption (Day 1).

Secondary outcomes

  1. Correlation Between Blood Alcohol Reduction and Breathalyzer Readings

    Correlation between the reduction in blood alcohol levels and breathalyzer (ethylometer) readings.

    Time frame: Baseline (30 minutes before), 20 minutes, 40 minutes, and 60 minutes after alcohol consumption (Day 1)

  2. Correlation Between Elimination Rate in Blood and Breathalyzer

    Correlation between the elimination rate of alcohol in blood and breathalyzer (ethylometer) readings.

    Time frame: Baseline (30 minutes before), 20 minutes, 40 minutes, and 60 minutes after alcohol consumption (Day 1).

  3. Hangover Symptom Severity Using AHSS

    Evaluation of Alcovit® efficacy in mitigating hangover symptoms using the total score and subdomains of the Alcohol Hangover Severity Scale (AHSS).

    Time frame: 24 hours after alcohol consumption (Day 1)

  4. Participant Experience with Alcovit® (Patient-Reported Outcomes)

    Participant experience with Alcovit® assessed by participant questionnaire.

    Time frame: Day 1 to Day 2

  5. Adverse Events Reported by Participants (Clinician-Reported Outcomes)

    Analysis of adverse events reported by participants.

    Time frame: Baseline (30 minutes before), 20 minutes, 40 minutes, and 60 minutes after alcohol consumption (Day 1)

  6. Number and Type of Adverse Events (Clinician-Reported Outcomes)

    Number and type of adverse events, unexpected adverse events, and serious adverse events.

    Time frame: Day 1 to Day 44 (6 weeks)

  7. Changes in Hepatic Function Markers (Clinician-Reported Outcomes)

    Changes in hepatic function between Alcovit® administration groups before and after alcohol ingestion (distilled and fermented beverages) compared to control for AST, ALT, GGT, alkaline phosphatase (ALP), total bilirubin and fractions.

    Time frame: Day 1 to Day 44 (6 weeks)

  8. Changes in Renal Function Markers (Clinician-Reported Outcomes)

    Changes in renal function between Alcovit® administration groups before and after alcohol ingestion (distilled and fermented beverages) compared to control for urea, creatinine, electrolytes, and urinalysis.

    Time frame: Day 1 to Day 44 (6 weeks)

  9. Ease of Handling and Administration (Clinician-Reported Outcomes/Patient-Reported Outcomes)

    Ease of handling and administration of Alcovit® assessed by questionnaire administered to nursing staff.

    Time frame: Day 1.

  10. Baseline Population Characteristics (Clinician-Reported Outcomes)

    Characterization of the study population and identification of potential confounding factors.

    Time frame: Day 1 (baseline)

07

Study locations

1 site
  • Hospital Santa Casa de Misericórdia de Campos
    Campos dos Goytacazes, Rio de Janeiro 28035-053, Brazil
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect participant privacy and confidentiality in accordance with Brazilian data protection laws (LGPD - Lei Geral de Proteção de Dados) and ethical requirements. Study results will be published in aggregated form only.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2027, 0 months later.

Of 328 non-industry interventional studies with no phase under Alcohol Drinking, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 0 months is below that.

Counting every sponsor, half of 336 studies reached it within 24 months; a quarter within 11 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start May 2026 → Jan 2027, primary completion May 2026 → Jan 2027 and completion May 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 12, 2026
StartEst.
Jan 20, 2027was May 2026
Primary completionEst.
Jan 20, 2027was May 2026
CompletionEst.
Jun 30, 2027was May 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 30, 2026→Jan 20, 2027
Nov 18, 2026
Primary completion
May 30, 2026→Jan 20, 2027
Nov 18, 2026
Study completion
May 30, 2027→Jun 30, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date May 30, 2026→Jan 20, 2027
    Primary completion May 30, 2026→Jan 20, 2027
    Study completion May 30, 2027→Jun 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07332429
Lead sponsor
Galzu Institute of Research, Teaching, Science and Applied Technology
Collaborators
Hospital Santa Casa de Misericordia de Campos
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Jan 20, 2027 (estimated)
Primary completion
Jan 20, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Marcelo P Coutinho, MD, PhD
Contact
coutinho_doc@hotmail.com
+55 22 992266669
Savio B Souza, PhD
Contact
institutogalzu@galzu.org.br
+55 22 999857370

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion